The momentum of RNA technologies is apparent in the significant increase in scientific knowledge, IP and deal-making value over recent years. Incorporating RNA to fight diseases have gained traction over the last decade and were lofted into public consciousness with the regulatory approvals of mRNA vaccines during the COVID-19 pandemic.
Success with different sorts of rare diseases, which have not responded well to traditional approaches, is setting RNA therapies apart and providing hope for patients and clinicians.
This report highlights seven companies that are taking innovative approaches to RNA therapies, from pioneering delivery methods to identifying novel targets.
By taking a closer look at these innovative RNA technology companies, this report will uncover:
- The potential benefits of their products for patients and caregivers
- Financing, patent filings and R&D activity to date
- What sets them apart from the pack and makes them companies to watch
Download the report to access detailed insights.